INFO60
SpotlightTopics60sNEWQuizLogin
IndiaAI & TechBusinessTechnologySportsEntertainmentHealthScienceWorld
INFO60

Know more. Read less. What matters, fast.

Company

  • About
  • Contact
  • Editorial Policy
  • Corrections
  • Our desks
  • Publishers

Legal

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Account

  • Delete Account
  • Spotlight
  • Quick Cards
  • Topics
  • Web Stories
  • Hindi News

Free. One email a day. Unsubscribe anytime.

Editions

  • India
  • United States
  • United Kingdom
  • Canada
  • Australia
  • UAE & Gulf
  • Singapore
  • Hindi
  • All countries
© 2026 Info60. All rights reserved.
Home›general›Anupam Rasayan Acquires 22.5 Lakh Shares Of Bliss GVS Pharma For ₹162.74 Crore
general

Anupam Rasayan Acquires 22.5 Lakh Shares Of Bliss GVS Pharma For ₹162.74 Crore

By Info60 India Desk•Summary of reporting by The Free Press Journal•2d ago•0 views•
Anupam Rasayan Acquires 22.5 Lakh Shares Of Bliss GVS Pharma For ₹162.74 Crore
Anupam Rasayan India Ltd has acquired an additional 22,50,000 equity shares of Bliss GVS Pharma Ltd through an on-market transaction.
ONLY AVAILABLE IN PAID PLANS
Read Full Article

Share this story

Report an error

Up next

Related Stories

निर्वाचन आयोग ने पिछले फैसलों की समीक्षा की: एसआईआर में सुनवाई और फॉर्म के नियम बदले; क्यों?

Amar Ujala

‘Conspiracy’ against Punjab, university & Hindu-Sikh unity: LPU Chancellor Ashok Mittal

‘Conspiracy’ against Punjab, university & Hindu-Sikh unity: LPU Chancellor Ashok Mittal

The Indian Express

Soon after SIR, Odisha’s Chief Electoral Officer applies VRS

Soon after SIR, Odisha’s Chief Electoral Officer applies VRS

The Hindu

Avoid ‘dangerous path’ of travelling to Russia to join army: MEA

Avoid ‘dangerous path’ of travelling to Russia to join army: MEA

The Hindu

‘A hero’: Trump on Indian pilot Smit Machchhar after mid-air cockpit attack

‘A hero’: Trump on Indian pilot Smit Machchhar after mid-air cockpit attack

The Indian Express

Comments (0)

Please login to comment

Login
💬

No comments yet. Be the first to comment!